Biologics Sports Medicine Organogenesis Provides Update on Second Phase 3 ReNu® Study byTim AllenSeptember 26, 2025
Financial Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance byJosh SandbergFebruary 29, 2024
Financial Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results byJosh SandbergMay 10, 2023
Financial Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results byChris StewartMay 10, 2022
Biologics Regulatory Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors byChris StewartMay 5, 2022
Financial Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance byJosh SandbergMarch 2, 2022
Biologics Regulatory Sports Medicine Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee byJosh SandbergJanuary 11, 2021
Financial Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 byJosh SandbergOctober 14, 2020
Biologics Financial Sports Medicine Organogenesis Holdings Inc. Announces Management Change byJosh SandbergAugust 24, 2020
Financial Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 byJosh SandbergJuly 15, 2020
